Nibulin AY-IsoLiPro

尼布林AY-IsoLiPro

Report date: 2023/02/28 17:51:26
NME

Base Information

Drug NameNibulin AY-IsoLiPro
Drug Alias Name尼布林AY-IsoLiPro（新型锂盐）
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsBipolar DisorderAlzheimer Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesAnyu Kampo Pharmaceutical (Huainan) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAnyu Kampo Pharmaceutical (Huainan) Co Ltd
Inactive CompaniesN/A
Active IndicationsBipolar DisorderAlzheimer Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A